Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
  • SBI Life
  • DSP Mutual Fund
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

Dr Reddy's completes clinical studies of its proposed rituximab biosimilar candidate

Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.

January 20, 2023 / 11:26 AM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Dr Reddy's Laboratories on Friday said it has successfully completed the full set of clinical studies of its proposed rituximab biosimilar candidate, 'DRL_RI' for filing in highly regulated markets such as the US, Europe and other regions.

In a BSE filing, it said 'DRL_RI' is being developed as a biosimilar of rituximab, for approval in the US, European Union and other regions for various indications including treatment of adult patients with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Following completion of the full set of clinical studies, Dr Reddy's said it will now prepare to file in the US, European Union and other regions for approval of 'DRL_RI'.

It has already been approved for marketing in India and over 25 emerging markets.